Sorrento Therapeutics (NASDAQ:SRNE) has added another arrow to its COVID-19 quiver. The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for patients with acute respiratory distress syndrome associated with COVID-19. Returns as of 11/03/2020. This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. SAN DIEGO - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, 'Sorrento') today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020. Cumulative Growth of a $10,000 Investment in Stock Advisor, Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline @themotleyfool #stocks $SRNE, These 2 Robinhood Favorites Could Double by 2022, 2 Coronavirus Stocks That Will Falter in a Market Crash. Financial terms of the deal weren't disclosed. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase 1B trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. But at some point, the biotech needs to stop discovering and licensing new treatments and spend more effort developing the treatments and getting them authorized by the FDA. ContactAlexis Nahama, DVM (SVP Corporate Development)Email: mediarelations@sorrentotherapeutics.com. STI-1499 and STI-2020 are neutralizing antibodies that bind directly to the coronavirus. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP, ACE-MAB, COVI-MAB, COVI-GUARD, COVI-SHIELD, COVI-AMG and T-VIVA-19 and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE. Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference ID: 2066037 Date of call: 10/13/2020 Time of call: 16:30 Eastern Time Let's conquer your financial goals together...faster. The MSC treatment was derived from fat cells, but the cells have the ability to turn into other types of tissue. Abivertinib was developed as a cancer treatment, but Sorrento hopes it could also help patients with COVID-19 by dampening the overactive immune system, which can cause problems in patients with COVID-19. Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutrali.. Chairman, President & Chief Executive Officer, VP-Pharmacovigilance & Clinical Operations. Robert Allen, SVP, Antiviral and Oncolytic Immunotherapy DevelopmentDr. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law. Alexis Nahama, SVP of Corporate Development, • Therapeutic Pipeline – Clinical Stage (Management), • Therapeutic Pipeline – IND enabling Stage (Management). "The data suggests stem cells have the ability to reduce inflammation, reduce scar tissue formation, and to aid in clearing the lungs of fluid," Robert Harman, CEO of Personalized Stem Cells, noted in May. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference ID: 2066037 Date of call: 10/13/2020Time of call: 16:30 Eastern TimeExpected Duration: 60 minutes + questions (analysts and general public). Forward-looking statements include statements regarding Sorrento’s pipeline and plans with respect to its strategic outlook and clinical and pre-clinical COVID-19 programs, its COVID-19 therapeutic and diagnostic product candidates and pipeline, and its proprietary technology platforms. Email: mediarelations@sorrentotherapeutics.com, (C) 2020 Electronic News Publishing, source ENP Newswire, https://edge.media-server.com/mmc/p/tun863t9. The main purpose of the early-stage study is twofold: Assess the safety of the treatment and measure its risk/benefit ratio. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations, including, but not limited to clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its therapeutic and diagnostic product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline The company's pipeline is large. Forward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Is Sorrento Therapeutics a Ticking Time Bomb for Investors? Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir', 'Seprehvec').

Terraonion Mega Sd, 10ft Swimming Pool Tesco, Miraculous Nouveau Héros, Homes For Sale In Warner, Nh, Emerald Cut Grillz, How To Reset Roomba Map,